Introduction {#s1}
============

Testicular cancer (TC) is the most common solid tumor affecting males between 20 and 40 years old and accounting for approximately 1--1.5% of all cancers in men ([@B1], [@B2]). In the last decades, its incidence showed a progressive increase, particularly in some regions of Europe and Northern America ([@B3]--[@B5]). It is a real variegate cancer, characterized by several histological patterns, comprising germ-cell tumors and non-germ-cell tumors. The former group is the most common and it is further subdivided into two histologic subtypes, namely, seminomas and non-seminomas ([@B6]).

Many risk factors have been proposed for TGCTs ([@B7], [@B8]) including cryptorchidism, genetics, and substances of abuse (i.e., drugs, smoke, and hormones). In addition, it is well known that some testicular lesions mimicking a testicular tumor are due to infectious pathology, especially in immunosuppressed patients. Nevertheless, the possible causal relationship between viral infections and TGCTs is still a subject of debate.

Despite the exposure to some viruses that have been certainly associated to other cancer types in males \[Epstein--Barr virus (EBV) for Burkitt lymphoma, human immunodeficiency virus (HIV) for Kaposi\'s sarcoma, hepatitis B virus (HBV) and hepatitis C virus (HCV) for hepatocellular carcinoma, and human papilloma virus (HPV) for penile, oropharyngeal, and anal cancers\], few studies evaluated the possible implications of viral infection in the pathogenesis of TGCTs. Curiously, most of the viruses involved in sexually transmittable disorders have an age-related prevalence that coincides with that observed in TGCTs. Moreover, the characteristic long latency and persistence in the host of several viruses could induce a long-term dysregulation of the cell cycle able to induce the cancer development. Again, some studies demonstrated the prevalence of viral DNA/RNA directly in tissue specimens from testicular cancer ([@B9]--[@B11]). Finally, it has been reported that EBV, as well as other DNA viruses, encodes a protein able to inactivate p53, a mechanism that is able to reduce apoptosis in tumor cells ([@B10], [@B12]).

In this meta-analysis, we aimed to summarize the whole body of literature exploring the correlation between TGCTs and viral infections by HPV, HIV, cytomegalovirus (CMV), EBV, and Parvovirus B-19, with the purpose of clarifying the possible role of these viruses in the pathogenesis of this condition.

Materials and Methods {#s2}
=====================

Study Design
------------

This is a systematic review and meta-analysis of published data. The review was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@B13]).

Ethical Approval
----------------

As this study was a systematic review and meta-analysis of published data, formal ethical approval was not required.

Search Strategy
---------------

Electronic databases (Sciencedirect, Medline, Scopus, Embase, the Cochrane library, Clinicaltrials.gov, EU Clinical Trials Register and World Health Organization International Clinical Trials Registry) were searched until 1st February 2019 (without date restriction).

Key search terms were as follows: virus OR viral infection OR viral disease OR human papillomavirus OR HPV OR Cytomegalovirus OR CMV OR Epstein--Barr virus OR EBV OR Parvovirus B19 OR human immunodeficiency virus OR HIV OR acquired immunodeficiency syndrome OR AIDS AND testicular cancer OR testicular neoplasm OR testicular tumor. The electronic search and the eligibility of the studies were independently assessed by two of the authors (AG and FM).

Inclusion Criteria
------------------

We included all studies evaluating the correlations between viral infections (i.e., HPV, CMV, EBV, Parvovirus B19, and HIV) and TGCTs. All observational studies (retrospective and prospective cohort studies, case and control series) reported in English were eligible. Testicular cancer was defined as the demonstration of testicular cancer cells at histopathological examination.

Study Selection and Data Extraction
-----------------------------------

Two authors (AG and AV) independently assessed the inclusion criteria and study selection. Disagreements were discussed with a third reviewer (CF).

Data extraction was performed by five independent investigators (AA, GA, FM, MG, and UV). When studies involved a subgroup of patients considered negligible for the endpoints of meta-analysis (e.g., patients affected by non-testicular cancer), the authors provided only a qualitative data extraction. A manual search of reference lists of studies was performed to avoid missing relevant publications. One author (AV) reviewed the selection and data extraction process. The results were then compared, and any disagreement was discussed and resolved by consensus.

Risk of Bias
------------

Two reviewers (AV and AG) independently judged the methodological quality of studies included in the meta-analysis using a modified version of the "Newcastle--Ottawa Scale" ([@B14]). Quality of studies was evaluated in five different domains: "*sample representativeness*," "*sampling technique*," "*ascertainment of viral infection*," "*quality of description of the population and confounders*," and "*incomplete data on cancer histology*" ([Table S1](#SM1){ref-type="supplementary-material"}). According to the total number of points assigned, each study was judged to be at low risk of bias (≥3 points) or high risk of bias (\<3 points). Any discrepancies concerning the author\'s judgments were referred to a third reviewer (CF) and resolved by consensus.

Statistical Analysis
--------------------

Odds ratios (ORs) and proportions were calculated with MedCalc 18.5 (MedCalc Software, Seoul, 158-051, Korea). For meta-analysis, Review Manager (RevMan) Version 5.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2011) was used. Statistical analysis was conducted using the "Generic inverse variance" method, where a pooled OR was determined from the natural logarithm (LN) of the studies\' individual OR \[LN (OR)\] and the 95% CI. The SE for the LN (OR) was calculated from the 95% CI using the formula: SE = \[LN (upper CI limit) -- LN (lower CI limit)\]/3.92, according to the Cochrane Reviewers\' handbook ([@B15]). Statistical heterogeneity was assessed by *I*^2^ statistics. The pooled estimates were reported graphically with Forest plots. Meta-analyses were conducted separately for each virus (HPV, EBV, CMV, Parvovirus B-19, and HIV). Sources of statistical heterogeneity were investigated by subgroups and sensitivity analyses (by serially excluding each study or study subgroups basing on methodological quality judgments).

Results {#s3}
=======

Study Selection
---------------

Starting from 198 selected abstracts, we evaluated 163 full texts regarding infection of interest in subjects with testicular cancer. Because of confounding conditions (infection after diagnosis of TC infection during or after radio and/or chemotherapy, animal studies, reviews, and case reports), 138 studies were excluded. Finally, a total of 25 studies were included in the present meta-analysis: 4 for HPV, 8 for EBV, 5 for CMV, 5 for Parvovirus B19, and 3 for HIV ([Figure 1](#F1){ref-type="fig"}).

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses **(**PRISMA) flow diagram of the review study on literature analysis for viral infection in subjects with testicular cancer. Some of the studies evaluated more than a virus.](fendo-10-00355-g0001){#F1}

Included Studies
----------------

Characteristics of included studies are summarized in [Table 1](#T1){ref-type="table"}. We included in the review a total of 19 studies. Four studies provided information for two viruses ([@B19], [@B21]--[@B23]) and one for three ([@B24]) viruses, reaching the number of 25. Studies embedded a total of 285,878 subjects. Most of the studies were case--control except for one case series, for both HPV and EBV ([@B19]) and one survey for HPV ([@B18]). All studies on HIV were cohort studies ([@B31]--[@B33]). Different techniques to diagnose viral infections were used. Most studies used PCR or detection of serum antibodies. Six studies used immune-histochemistry (IHC), four used *in situ* hybridization (ISH), one used fluorescent *in situ* hybridization (FISH), and one used immunofluorescent staining (IFS).

###### 

General features of included studies.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Virus**   **References**                     **Country**   **Setting**     **Population**   **Method**                          **Measure**       **Result (95% CI)**
  ----------- ---------------------------------- ------------- --------------- ---------------- ----------------------------------- ----------------- ---------------------
  HPV         Bertazzoni et al. ([@B16])         Italy         Case--control   Cases 61\        PCR                                 Percentage        0% Cases\
                                                                               Controls 23                                                            0% Controls

  HPV         Garolla et al. ([@B17])            Italy         Case--control   Cases 155\       PCR and FISH                        Percentage        9.7% Cases\
                                                                               Controls 84                                                            2.4% Controls

  HPV         Strickler et al. ([@B18])          USA           Survey          Total 87\        ELISA                               Percentage        5% of TC
                                                                               (TC 39)                                                                

  HPV         Rajpert-De Meyts et al. ([@B19])   Denmark       Case series     Cases 19\        PCR and IHC                         Number of cases   0% Cases\
                                                                               Controls 1                                                             0% Controls

  EBV         Moss et al. ([@B20])               USA           Case--control   Cases 173\       Interview                           OR                0.6 (0.3--1.1)
                                                                               Controls 217                                                           

  EBV         Algood et al. ([@B21])             USA           Case--control   Cases 56\        Serology                            Percentage        80% Cases\
                                                                               Controls 30                                                            30% Controls

  EBV         Akre et al. ([@B22])               Norway        Case--control   Cases 81\        Serology                            OR                2.74 (0.62--12.12)
                                                                               Controls 242                                                           

  EBV         Shimkage et al. ([@B10])           Japan         Case--control   Cases 27\        PCR, IHC, and IFS                   Percentage        100% Cases\
                                                                               Controls 25                                                            0% Controls

  EBV         Heinzer et al. ([@B23])            Germany       Case--control   Cases 53\        Serum antibodies                    OR                6.93 (0.8--59.8)
                                                                               Controls 51                                                            

  EBV         Gray et al. ([@B24])               Switzerland   Case--control   Cases 39\        PCR                                 Percentage        0% Cases\
                                                                               Controls 12                                                            0% Controls

  EBV         Rajpert-De Meyts et al. ([@B19])   Denmark       Case series     Cases 19\        PCR, IHC, and ISH non-radioactive   Proportion        6/19
                                                                               Controls 1                                                             

  EBV         Fend et al. ([@B25])               Austria       Case--control   Cases 32\        PCR and ISH non-radioactive         Percentage        12.5% Cases\
                                                                               Controls 5                                                             0% Controls

  CMV         Mueller et al. ([@B26])            Sweden        Case--control   Cases 117\       Serology                            R.R.              2.0 (1.1--3.6)
                                                                               Controls 100                                                           

  CMV         Akre et al. ([@B22])               Norway        Case--control   Cases 81\        Serology                            OR                1.08 (0.6--1.94)
                                                                               Controls 242                                                           

  CMV         Algood et al. ([@B21])             USA           Case--control   Cases 56\        Serology                            Percentage        50% Cases\
                                                                               Controls 10                                                            10% Controls

  CMV         Heinzer et al. ([@B23])            Germany       Case--control   Cases 47\        ISH and Serum antibodies            Percentage        4.2% Cases\
                                                                               Controls 47                                                            0% Controls

  CMV         Gray et al. ([@B24])               Switzerland   Case--control   Cases 39\        PCR                                 Percentage        0% Cases\
                                                                               Controls 12                                                            0% Controls

  Parvo B19   Polzc et al. ([@B27])              USA           Case--control   Cases 23\        PCR and IHC                         Percentage        73.9% Cases\
                                                                               Controls 7                                                             85.7% Controls

  Parvo B19   Gray et al. ([@B24])               Switzerland   Case--control   Cases 39\        PCR                                 Percentage        85% Cases\
                                                                               Controls 12                                                            0% Controls

  Parvo B19   Ergunay et al. ([@B28])            Turkey        Case--control   Cases 56\        PCR                                 Percentage        5.4% Cases\
                                                                               Controls 66                                                            0% Controls

  Parvo B19   Tolfvenstam et al. ([@B29])        Norway        Case--control   Cases 77\        PCR, Serology and IHC               OR                1.03 (0.6--1.77)
                                                                               Controls 238                                                           

  Parvo B19   Diss et al. ([@B30])               UK            Case--control   Cases 20\        PCR and IHC                         OR                1.01 (0.59--1.72)
                                                                               Controls 10                                                            

  HIV         Dihr et al. ([@B31])               India         Cohort          Total 251\       Serology                            PIR               2.5 (1.04--6.05)
                                                                               (5 TC)                                                                 

  HIV         Goedert et al. ([@B32])            USA           Cohort          Total 268.950\   Serology                            SIR               1.7 (1.5--1.9)
                                                                               (217 TC)                                                               

  HIV         Grulich et al. ([@B33])            Australia     Cohort          Total 13.067\    Serology                            SIR               1.46 (0.7--2.69)
                                                                               (10 TC)                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*FISH, fluorescent in situ hybridization; IHC, immune-histochemistry; IFS, immunofluorescent staining; ELISA, enzyme-linked immunosorbent assay; PIR, proportioned incidence ratio*.

Assessment of the Risk of Study Bias
------------------------------------

In [Table 2](#T2){ref-type="table"}, the criteria used to assess the risk of study bias are reported.

1.  -- *Sample representativeness:* All but six studies ([@B10], [@B19], [@B24], [@B25], [@B27], [@B30]) were judged at low risk of bias for sample representativeness.

2.  -- *Sampling technique*: Eleven studies ([@B16], [@B17], [@B20]--[@B22], [@B24], [@B26], [@B29], [@B31]--[@B33]) had adequate sampling strategy (random or consecutive). Other studies did not provide data.

3.  -- *Ascertainment of viral infection:* One study ([@B20]) was judged at high risk of bias because the diagnosis of viral infection was based on self-administered questionnaires. The remaining studies were at low risk of bias.

4.  -- *Quality of description of the population and confounders:* Only three studies were considered at low risk of bias ([@B17], [@B20], [@B28]). Other studies did not provide adequate description of the study population and/or confounders.

5.  -- *Incomplete data on histology*: All but two studies ([@B17], [@B31]) provided adequate data on cancer histotypes.

6.  -- *Overall study quality*: In summary, pooling of scores for each domain resulted in five studies to be at high risk of bias ([@B10], [@B19], [@B25], [@B27], [@B30]). The remaining studies were at low risk of bias ([@B16]--[@B18], [@B20]--[@B24], [@B26], [@B28], [@B29], [@B31]--[@B33]).

###### 

Authors\' judgment of study quality according to the "Modified Newcastle--Ottawa Risk of Bias Scoring System."

  **References**                     **Sample representativeness**       **Sampling technique**              **Diagnostic accuracy**             **Confounders description**         **Cancer histology**                **Total score**   **Risk of bias**
  ---------------------------------- ----------------------------------- ----------------------------------- ----------------------------------- ----------------------------------- ----------------------------------- ----------------- ------------------
  Bertazzoni et al. ([@B16])         [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Garolla et al. ([@B17])            [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       4                 LOW
  Polzc et al. ([@B27])                                                                                      [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   2                 HIGH
  Moss et al. ([@B20])               [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Algood et al. ([@B21])             [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Akre et al. ([@B22])               [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Shimkage et al. ([@B10])                                                                                   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   2                 HIGH
  Heinzer et al. ([@B23])            [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   3                 LOW
  Gray et al. ([@B24])                                                   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   3                 LOW
  Rajpert-De Meyts et al. ([@B19])                                                                           [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   2                 HIGH
  Fend et al. ([@B25])                                                                                       [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   2                 HIGH
  Mueller et al. ([@B26])            [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Ergunay et al. ([@B28])            [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Tolfvenstam et al. ([@B29])        [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Diss et al. ([@B30])                                                                                       [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   2                 HIGH
  Strickler et al. ([@B18])          [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   3                 LOW
  Dihr et al. ([@B31])               [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                                                           3                 LOW
  Goedert et al. ([@B32])            [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   4                 LOW
  Grulich et al. ([@B33])            [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}   [^\*^](#TN1){ref-type="table-fn"}                                       [^\*^](#TN1){ref-type="table-fn"}   4                 LOW

The symbol

*indicate the presence of the criterion considered in the table*.

Synthesis of Results
--------------------

### Human Papilloma Virus

A total of four studies evaluated the correlation between HPV infection and TGCTs. The pooled sample of patients analyzed was 430, of whom 274 were affected by TGCTs and 156 were healthy controls ([Figure 2](#F2){ref-type="fig"}). In two studies, the search for HPV was conducted on histological sections from testicular tissue using PCR ([@B16], [@B19]). In the remaining two studies, the diagnosis of HPV infection was achieved by detection of serum antibodies ([@B18]) and by evaluating sperm infection by FISH and PCR ([@B17]).

![Forest plot: Human papilloma virus (HPV) and testicular cancer.](fendo-10-00355-g0002){#F2}

Pooling of results did not show an association between HPV infection and TGCTs (OR 2.79, 95% CI 0.84--9.29, *p* = 0.09, *I*^2^ = 0%). Sensitivity analysis did not provide statistical changes to aggregate results. Subgroup analysis was not feasible.

### Epstein--Barr Virus

A total of eight studies evaluated the correlation between EBV infection and TGCTs. The pooled sample of patients analyzed was 1,063, of whom 480 were affected by TGCTs and 583 were controls ([Figure 3](#F3){ref-type="fig"}). In four studies, the search for EBV was conducted on histological sections from testicular tissue by using ISH, IFS, and PCR ([@B10]); PCR ([@B24]); and PCR, IHC, and on-radioactive ISH ([@B19], [@B25]). In a single study, the history of EBV infection was evaluated by telephone interview ([@B20]). In the remaining three studies, EBV diagnosis was achieved by detection of serum antibodies ([@B21]--[@B23]).

![Forest plot: Epstein--Barr virus (EBV) and testicular cancer.](fendo-10-00355-g0003){#F3}

Pooling of results did not show an association between EBV infection and TGCTs (OR 4.78, 95% CI 1.01--22.64, *p* = 0.05), with high degree of statistical heterogeneity (*I*^2^ = 84%). The exclusion of the study by Moss et al. from meta-analysis resulted in a significant association between EBV and TGCTs (OR 7.38, 95% CI 1.89--28.75, *p* = 0.004, *I*^2^ = 59%). Subgroup analysis based on the methods for EBV determination (serology vs. testicular tissue analysis vs. interview) found a significantly higher risk of TGCTs in those patients with a positive serology (test for subgroup differences: χ^2^ = 24.1, *p* \< 0.00001). The proportion of seminomas among EBV+ patients (at serology) with a diagnosis of TGCTs was 51.69% (95% CI 44.01--59.32%).

### Cytomegalovirus

A total of five studies evaluated the correlation between CMV infection and TGCTs ([Figure 4](#F4){ref-type="fig"}). The pooled sample of patients analyzed was 751, of whom 340 were affected by TGCTs and 411 were controls. In a single study, the search for CMV was conducted on histological sections from testicular tissue by PCR ([@B24]). In four studies, CMV diagnosis was achieved by detection of serum antibodies ([@B22], [@B23], [@B26]). One study used indirect immunofluorescence assay ([@B21]).

![Forest plot: Cytomegalovirus (CMV) and testicular cancer.](fendo-10-00355-g0004){#F4}

Pooling of results did not show an association between CMV infection and TGCTs (OR 1.81, 95% CI 0.92--3.57, *p* = 0.09), with moderate statistical heterogeneity (*I*^2^ = 45%). The exclusion of the study by Akre et al. from the meta-analysis resulted in a significant association between CMV and TGCTs (OR 2.38, 95% CI 1.24--4.53, *p* = 0.009) and reduced the heterogeneity (*I*^2^ = 4%). The proportion of seminomas among CMV+ patients (at serology) with a diagnosis of TGCTs was 50.47% (95% CI 42.95--57.97%). Subgroup analysis was not feasible.

### Parvovirus B-19

A total of five studies evaluated the correlation between Parvovirus B-19 infection and TGCTs ([Figure 5](#F5){ref-type="fig"}). The pooled sample of patients analyzed was 548, of whom 215 were affected by TGCTs and 333 were controls. In a single study, the search for Parvovirus B-19 was conducted by detection of serum antibodies ([@B29]). In four studies, Parvovirus B-19 diagnosis was achieved by analyzing samples of testicular tissue by PCR and IHC ([@B27], [@B30]) or only PCR ([@B24], [@B28]).

![Forest plot: Parvovirus B-19 and testicular cancer.](fendo-10-00355-g0005){#F5}

Pooling of results did not show an association between Parvovirus B-19 infection and TGCTs (OR 1.85, 95% CI 0.37--9.15, *p* = 0.45), with substantial statistical heterogeneity (*I*^2^ = 73%). The serial exclusion of each single study through sensitivity analysis as well as subgroup analysis did not modify the results of the primary analysis.

Human Immunodeficiency Virus
----------------------------

A total number of three cohort studies ([@B31]--[@B33]) evaluated the correlation between HIV infection and testicular cancer ([Figure 6](#F6){ref-type="fig"}). The pooled sample of patients analyzed was 282,268 HIV+, of whom 232 were affected by TGCTs. In all patients, the diagnosis of HIV was confirmed by serology.

![Forest plot: Human immunodeficiency virus (HIV) and testicular cancer.](fendo-10-00355-g0006){#F6}

Pooling of results showed a significant association between HIV infection and TGCTs (OR 1.71, 95% CI 1.51--1.93, *p* \< 0.00001), with low heterogeneity (*I*^2^ = 0%). The serial exclusion of each single study through sensitivity analysis did not modify the results of the primary analysis. The proportion of seminomas among HIV+ patients with a diagnosis of TGCTs was 75.17% (95% CI 69.01--80.66%).

Discussion {#s4}
==========

Testicular cancer is the most common neoplasm affecting males between 20 and 40 years old and accounting for approximately 1--1.5% of all cancers in men ([@B1], [@B2]). It embraces several histotypes of cancer, classified into the two main groups of seminomas and non-seminomas by the World Health Organization ([@B6]).

The pathogenesis of TGCTs is poorly known ([@B34]). Genetic factors play an important role in the development of this disease, as demonstrated by the modified expression of specific genes in testicular cancer cells ([@B34], [@B35]). Moreover, the exposition to different environmental agents, such as pesticides and non-steroidal estrogens (i.e., diethylstilbestrol), can increase the risk of developing this neoplasm ([@B35], [@B36]). Additional risk factors correlated to the onset of TGCTs are cryptorchidism, Klinefelter\'s syndrome, congenital abnormalities, and infertility ([@B2], [@B8]).

Recent efforts in oncological and virological research have brought to light the oncogenic potential of different virus species ([@B37]). It is now estimated that \~10% of worldwide cancers are attributable to viral infections, with the vast majority (85%) occurring in the developing world ([@B37], [@B38]). A possible causal relationship between viral infections and TGCTs was firstly evoked almost 40 years ago. Newell et al. ([@B39]) postulated a "viral theory" starting from the evidence of a similar geographical and age distribution of TGCTs and classical Hodgkin\'s lymphoma. In Hodgkin\'s lymphoma, the malignant Reed--Sternberg cells display a monoclonal profile where EBV DNA and RNA have been clearly identified ([@B40], [@B41]). Differently, data about EBV DNA and RNA within TGCT cells are few and the etiopathogenetic role of EBV in testicular carcinogenesis is still a matter of debate.

In the recent past, different authors have argued about a possible role of other oncogenic viruses in the development of TGCTs, including CMV, HIV, HPV, and Parvovirus B-19. The aim of this present review was to summarize the available evidence on the impact of viral infections on the risk of developing TGCTs.

Main Findings and Interpretation
--------------------------------

A total of 19 studies ([@B10], [@B16]--[@B33]) were included in this present systematic review and meta-analysis.

The correlation between HPV infection and TGCTs was evaluated by four studies on 430 patients ([@B16]--[@B18], [@B31]). Statistical analysis failed to demonstrate a statistical correlation between HPV infection and increased risk of TGCTs (*p* = 0.09). Notably, there was high between-studies heterogeneity in terms of methodology, potentially limiting drawing firm conclusions from the data.

HPV is one of the most common sexually transmitted viruses ([@B42]). It is particularly common in a young sexually active population and its prevalence is closely related to sexual behavior ([@B3]). During infection, HPV gains access to the interior of the cells, exerting a direct control on the proliferation and apoptosis of host cells ([@B43]). Once inside the cell, HPV DNA can transition from an episomal to a host genome integrated form, thus regulating cell genome transcription. Two specific HPV genes, namely, E6 and E7, are highly conserved among oncogenic HPV genotypes ([@B44], [@B45]). These genes can promote cellular transformation and alter the pathways related to the immune response, leading to carcinogenesis in a plethora of human tissues including vulva, vagina, penis, anus, head, neck, and oropharyngeal cavity ([@B46], [@B47]). In the testis, HPV is capable of directly infecting the male gametes, resulting in reduced fertility due to increased sperm DNA fragmentation and aneuploidy. It is thought that HPV is attached to the spermatozoa in two distinct sites along the equatorial region of the spermatozoon\'s head, similarly to other viruses infecting the sperm ([@B42], [@B48]).

Nevertheless, concurrently with new insights about infertility causes and treatments ([@B49], [@B50]), we must stress that the majority of recent studies on HPV in males have focused on the impact of viral infection on fertility, oocyte fertilization rate, and miscarriage rate in assisted reproduction technologies (ARTs) ([@B51], [@B52]). Conversely, the data on the association between HPV and TGCTs are scanty. Given the well-known oncogenic potential of HPV and considering its tropism for testicular tissue, the role of this virus in testicular carcinogenesis cannot be excluded. Future good-quality evidence is still needed to clarify the issue.

The association between EBV infection and TGCTs was investigated by eight studies on 1,063 patients ([@B10], [@B19]--[@B25]). While pooling of results from all studies did not show an association between EBV infection and TGCTs (*p* = 0.05), the exclusion of a single study from meta-analysis ([@B20]) resulted in a significant association between EBV and TGCTs (*p* = 0.004). Importantly, the study by Moss et al. ([@B20]) was at high risk of detection bias (i.e., the infection was investigated through a telephone interview), potentially distorting the final effect estimates from meta-analysis. Additionally, subgroup analysis (based on the methods for EBV determination) found a significant higher risk of TGCTs in those patients with a positive serology (*p* \< 0.00001), further confirming the association between history of EBV infection and TGCTs onset.

EBV was the first virus shown to cause cancer in humans ([@B53]). Besides the well-known association between EBV and Burkitt lymphoma (discovered by Michael Anthony Epstein and Yvonne Barr in 1964) ([@B54]), this virus was found to be associated with many other lymphoid, epithelial, and mesenchymal cancers ([@B55]). EBV can promote carcinogenesis in both immune-competent hosts and immune-compromised patients (i.e., those who have undergone organ transplantation or who are under immune-suppressive treatments) ([@B53], [@B56]). The mechanisms of EBV-induced carcinogenesis rely on extensive methylation of the host genome, which promotes viral propagation and cellular transformation. The most common oncogenic DNA modifications associated with EBV are phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations, extreme DNA hypermethylation, and amplification of the Janus activated kinase2 (JAK2) ([@B57], [@B58]).

Regarding EBV and TGCTs, there is an epidemiological correlation between these two entities. The incidence of infectious mononucleosis (including EBV-correlated orchitis) is higher in Europe and North America, similar to that of TGCTs. Interestingly, both infectious mononucleosis and TGCTs mainly occur in adolescents, suggesting that testicular differentiation is a factor increasing the susceptibility for both EBV infection and testicular carcinogenesis. ([@B10]) Moreover, nasopharyngeal carcinoma (which is linked to EBV) and TGCTs have some common characteristics, including age peak incidences in adolescents and chemoresponsiveness to cisplatin ([@B59]). Therefore, this present review found adequate evidence supporting a role for EBV in TGCTs development.

The correlation between CMV infection and TGCTs was investigated by five studies, including 751 patients ([@B19], [@B21]--[@B24], [@B26]). While pooling of results did not show an association between CMV infection and TGCTs (*p* = 0.09), the exclusion of a single study ([@B22]) from meta-analysis resulted in a significant association between CMV and cancer (*p* = 0.009). Notably, the methodological quality of the study by Akre et al. ([@B22]) was fair. Therefore, based on available data, the correlation between CMV and TGCTs cannot be sustained.

CMV is a ubiquitous herpes virus that leads to a lifelong persistence ([@B60]). The prevalence of CMV infection is extremely high in the general adult population (from 50 to 100%) and the virus is not considered to be oncogenic ([@B61]). Probably, due to the high prevalence of the infection, a larger sample of patients would be required to show (or repudiate) any correlation between CMV and TGCTs.

Actually, even if CMV can lead to dramatic complications in immunocompromised individuals, murine experiments repeatedly failed to demonstrate a clear ongogenic activity for this virus ([@B62], [@B63]). In this regard, some authors postulated that CMV may contribute to oncogenesis by "hit-and-run" mechanisms, namely, by inducing human cell transformation and successively disappearing by malignant cell clones ([@B64], [@B65]). However, this theory is not adequately supported by scientific data and the oncogenic potential of CMV is still obscure.

A total of five studies (on 548 patients) evaluated the correlation between Parvovirus B-19 infection and TGCTs ([@B24], [@B27]--[@B30]). Pooling of results failed to demonstrate an association between Parvovirus B-19 infection and TGCTs (*p* = 0.45). Additionally, subgroup and sensitivity analyses did not modify the results of the primary analysis, confirming their robustness. Parvovirus B-19 is the only parvovirus known to be pathogenic for humans ([@B66]). The virus exhibits a particular tropism for erythroid cells and can rarely cause dramatic complications in humans ([@B67], [@B68]). In immunocompetent hosts, the virus can cause acute, generally self-limiting clinical manifestations including the fifth disease in children and acute polyarthritis in adults ([@B66]). In immunosuppressed hosts (including pregnant women), Parvovirus B-19 may cause severe complications including glomerulonephritis, vasculitis, peripheral neuropathies, myocarditis, fulminant hepatic failure, and aplastic anemia ([@B69], [@B70]). There is no robust evidence supporting the role of this virus in human cells oncogenesis, even if a recent study showed a possible correlation with thyroid cancer ([@B71]). However, available data do not support the role of Parvovirus B-19 in the etiology of TGCTs.

Three studies, performed on 282,268 patients, evaluated the correlation between HIV infection and TGCTs ([@B31]--[@B33]), showing a significant association between these two entities (*p* \< 0.00001). The results were robust and displayed a low statistical heterogeneity (*I*^2^ = 0%).

The correlation between HIV-induced immunodeficiency and increased cancer risk has long been known ([@B72]). In immunocompetent people, the immune system has the ability to suppress oncogenic viruses and exert a continuous surveillance for malignant cells. These biological functions can fail when the immune system is impaired by HIV infection ([@B73], [@B74]). Therefore, HIV infection may promote testicular carcinogenesis mainly through indirect effects on the regulation of cell proliferation and apoptosis ([@B72]). Conversely, a direct effect of HIV on proto-oncogen expression in the human testis has not been demonstrated.

Interestingly, the majority of men dying of AIDS have hypospermatogenesis, spermatogenic arrest, or a Sertoli-cell-only testicular histology ([@B75], [@B76]). These histological changes are typically found in patients with TGCTs, supporting the theory that men with HIV may display a premalignant testicular atrophy. This premalignant condition may be due to the general debilitating effects of HIV rather than due to specific HIV-related mechanisms. To support this hypothesis, those patients effectively treated with antiretroviral drugs have a decreased incidence of testicular atrophy and TGCTs ([@B77], [@B78]). Therefore, we can conclude that HIV is associated with a significant higher risk of TGCTs, but effective antiretroviral therapy may considerably attenuate the risk of suffering from this condition.

Strength and Limitations
------------------------

The present meta-analysis comprehensively evaluates the impact of viral infection on TGCTs risk. We planned sensitivity and subgroup analysis in order to reduce bias related to study heterogeneity. Moreover, we created a modified Newcastle--Ottawa scoring system (*ad hoc*) in order to provide a methodological quality judgment for each study that may help readers in a proper interpretation of the study findings. However, our results are considerably limited by the small number of patients included in specific comparisons, heterogeneity in the study designs and methods, poor methodological quality of some studies (the majority were retrospective studies), and some concerns about the ascertainment of viral infection. In particular, while some studies used sensitive techniques to test viral infections, other studies, like those ones on HIV, based their results on the detection of serum antibodies. Moreover, only few studies reported the presence of other risk factors for the development of testicular cancer. Therefore, even if a relationship between specific viruses and testicular cancer was detected by the present meta-analysis, causation cannot be established.

Conclusions {#s5}
===========

We found a possible correlation between specific viruses and testicular cancer, but the evidence was insufficient to establish causality. The correlation between HIV and increased risk of TGCTs is supported by good-quality evidence despite being based on serum antibody titers. Similarly, the evidence suggesting a link between EBV and TGCTs is fair.

Regarding the correlation between CMV and TGCTs, available data are conflicting and further studies are needed to draw firm conclusions. Moreover, poor evidence supports the lack of correlation between Parvovirus B-19 and a meaningful risk of TGCTs. Finally, data about the possible relationship between HPV and TGCTs are inconsistent, but its oncogenic potential for male gonadal tissue cannot be excluded; thus, future good-quality studies are warranted.
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###### 

Risk of bias evaluation. Quality of studies included in the meta-analysis was evaluated using five different domains through a modified version of the "Newcastle--Ottawa Scale" ([@B14]).
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Click here for additional data file.
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